Adult Initially 15 mg once daily, may be increased to 30 mg once daily after at least 24 hr. Max: 60 mg once daily. Max duration of therapy: Not >30 days.
Patients should be monitored to assess serum Na conc & neurologic status especially during initiation & after titration. Discontinue or interrupt treatment if patients develop too rapid arise in serum Na. Risk of serious liver injury; dehydration & hypovolemia; hyperkalemia. Discontinue in case of symptoms that may indicate liver injury; or significant signs & symptoms of dehydration & hypovolemia. Avoid use in patients w/ underlying liver disease including cirrhosis. Monitor serum K levels after initiation of therapy in patients w/ K >5 mEq/L or on drugs known to increase K. Concomitant use w/ hypertonic saline is not recommended. Avoid concomitant use w/ CYP3A inducers or moderate CYP34 inhibitors. Dose reduction when co-administered w/ P-gp inhibitors. Not recommended in patients w/ CrCl <10 mL/min. Pregnancy & lactation.
Sign Out
